Theraclion Delivers Its 2023 Strategic Objectives - Seite 2

A new milestone: 2,000 veins treated with SONOVEIN.

Following on from the 1,000 veins treated in 2022, this year Theraclion has treated 2,000 veins with its SONOVEIN robotic platform. No severe adverse events have been reported, confirming the technology's excellent safety profile. Such acceleration demonstrates the method's capacity for adoption by centers and its relevance for patients and doctors alike.

Exploring potential in breast cancer treatment

In the first half of the year, the Cancer Center at the University of Virginia in the United States acquired the latest generation SONOVEIN HD for the launch of a new clinical trial, approved by the FDA. The aim is to assess the combined effects of High Intensity Focused Ultrasound (HIFU) and chemotherapy in patients with early-stage breast cancer. This study could pave the way to a new market with considerable global potential.

Funding secured for 2024

The company has stepped up its efforts to ensure sound financial management, in particular by controlling its expenditure. As budget forecasts currently stand, 2024 should be fully covered financially.

About Theraclion

Theraclion is a French MedTech company committed to developing a non-invasive alternative to surgery through the innovative use of focused ultrasound.

High Intensity Focused Ultrasound (HIFU) does not require incisions nor an operating room, leaves no scars, and allows patients an immediate return to their daily activities. Echotherapy, as the HIFU treatment method is called, concentrates therapeutic ultrasounds to an internal focal point from outside of the body.

Theraclion has developed two CE-marked robotic platforms delivering echotherapy: SONOVEIN for varicose veins and ECHOPULSE for breast fibroadenoma and thyroid nodules. Each representing the potential to replace millions of surgical procedures every year.

Based in Malakoff (Paris), the Theraclion team is made up of 30 people, mainly in technological and clinical development.

For more information, please visit www.theraclion.com or www.echotherapy.com and follow the account on LinkedIn.

Theraclion is listed on Euronext Growth Paris
Eligible for the PEA-PME scheme
Mnemonic: ALTHE - ISIN code: FR0010120402
LEI: 9695007X7HA7A1GCYD29

View source version on businesswire.com: https://www.businesswire.com/news/home/20231214478206/en/

The Theraclion Stock at the time of publication of the news with a fall of -0,28 % to 0,361EUR on Lang & Schwarz stock exchange (14. Dezember 2023, 18:30 Uhr).